EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Evolus, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$7.36+0.26 (+3.66%)

Close on Oct 19, 2026

Market cap: $485.24M
P/E (TTM): –
Dividend yield: –

Dividends

Evolus has not reported a dividend

No dividend per share appears in Evolus's annual filings since fiscal 2016.

Where these numbers come from

Parsed from the XBRL in Evolus's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is EOLS.

Revenue growth13.9% · median -1.4%

Gross margin66.7% · median 77.6%

Operating margin-5.9% · median 7.4%

Net margin-10.8% · median 6.1%

Company	Revenue	Growth
PBH	$1.10B	-1.4%
ARQT	$463.98M	+76.1%
EOLS	$316.49M	+13.9%
RIGL	$276.79M	+3.3%
AMRN	$186.23M	-15.1%
LFVN	$182.59M	-20.1%

Company

Next earnings (est.): Nov 4, 2026, during market hours
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 334
Held by institutions: 84.0%
Auditor: Ernst & Young LLP
SEC CIK: 1570562

Advertisement
300 × 250